Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**FLUSODEX-45** is a 500 mL fixed-dose intravenous infusion marketed by Otsuka Pharmaceutical India that contains glucose 5% w/v and sodium chloride 0.45% w/v. It provides water, sodium, chloride, and carbohydrate calories for intravenous fluid and electrolyte replacement, including management of dehydration or hypovolemia when water, sodium chloride, and carbohydrate supplementation are required. Its clinical activity is physicochemical replacement rather than receptor-mediated pharmacology. ([otsukapharma.in](https://otsukapharma.in/what-we-make/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on glucose + sodium chloride (Otsuka Pharmaceutical India).